According to a major international study, Switzerland has once again fallen behind other European countries in terms of access to new innovative medicines – from sixth to seventh place. Particularly worrying is the fact that, compared to Germany, only around half as many new innovative medicines are reimbursed as standard via the specialty list.
Autoren
- Mirjam Peter, M.Sc.
Publikation
- DERMATOLOGIE PRAXIS
Related Topics
You May Also Like
- AI in neurology
Control instead of a flood of data: AI makes big data and wearables usable
- From symptom to diagnosis
Abdominal pain – Sprue
- Case Report
76-year-old patient with pustular skin rash
- Sponsored Content: Psoriasis
Dauerhafte Erscheinungsfreiheit auch bei betroffenen speziellen Hautarealen
- Antithymocyte globulin in children with T1D
Old medicine, new hope
- Ginkgo biloba
Database of preclinical and clinical studies is becoming increasingly larger
- Digital biomarkers
Continuous monitoring using digital biomarkers in MS care
- Benefits, limits and safety aspects